179 related articles for article (PubMed ID: 10586342)
1. High antitumour activity of ET743 against human tumour xenografts from melanoma, non-small-cell lung and ovarian cancer.
Hendriks HR; Fiebig HH; Giavazzi R; Langdon SP; Jimeno JM; Faircloth GT
Ann Oncol; 1999 Oct; 10(10):1233-40. PubMed ID: 10586342
[TBL] [Abstract][Full Text] [Related]
2. Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts.
Valoti G; Nicoletti MI; Pellegrino A; Jimeno J; Hendriks H; D'Incalci M; Faircloth G; Giavazzi R
Clin Cancer Res; 1998 Aug; 4(8):1977-83. PubMed ID: 9717828
[TBL] [Abstract][Full Text] [Related]
3. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
[TBL] [Abstract][Full Text] [Related]
4. Preclinical and clinical results with the natural marine product ET-743.
D'Incalci M; Jimeno J
Expert Opin Investig Drugs; 2003 Nov; 12(11):1843-53. PubMed ID: 14585059
[TBL] [Abstract][Full Text] [Related]
5. The combination of yondelis and cisplatin is synergistic against human tumor xenografts.
D'Incalci M; Colombo T; Ubezio P; Nicoletti I; Giavazzi R; Erba E; Ferrarese L; Meco D; Riccardi R; Sessa C; Cavallini E; Jimeno J; Faircloth GT
Eur J Cancer; 2003 Sep; 39(13):1920-6. PubMed ID: 12932672
[TBL] [Abstract][Full Text] [Related]
6. Ecteinascidin 743: a novel anticancer drug with a unique mechanism of action.
Aune GJ; Furuta T; Pommier Y
Anticancer Drugs; 2002 Jul; 13(6):545-55. PubMed ID: 12172500
[TBL] [Abstract][Full Text] [Related]
7. Poisoning of human DNA topoisomerase I by ecteinascidin 743, an anticancer drug that selectively alkylates DNA in the minor groove.
Takebayashi Y; Pourquier P; Yoshida A; Kohlhagen G; Pommier Y
Proc Natl Acad Sci U S A; 1999 Jun; 96(13):7196-201. PubMed ID: 10377391
[TBL] [Abstract][Full Text] [Related]
8. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
Twelves C; Hoekman K; Bowman A; Vermorken JB; Anthoney A; Smyth J; van Kesteren C; Beijnen JH; Uiters J; Wanders J; Gomez J; Guzmán C; Jimeno J; Hanauske A
Eur J Cancer; 2003 Sep; 39(13):1842-51. PubMed ID: 12932661
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation of two human cancer cell lines selected in vitro for their chemotherapeutic drug resistance to ET-743.
Marchini S; Marrazzo E; Bonomi R; Chiorino G; Zaffaroni M; Weissbach L; Hornicek FJ; Broggini M; Faircloth GT; D'Incalci M
Eur J Cancer; 2005 Jan; 41(2):323-33. PubMed ID: 15661559
[TBL] [Abstract][Full Text] [Related]
10. Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.
Sessa C; De Braud F; Perotti A; Bauer J; Curigliano G; Noberasco C; Zanaboni F; Gianni L; Marsoni S; Jimeno J; D'Incalci M; Dall'ó E; Colombo N
J Clin Oncol; 2005 Mar; 23(9):1867-74. PubMed ID: 15774779
[TBL] [Abstract][Full Text] [Related]
11. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer.
Zelek L; Yovine A; Brain E; Turpin F; Taamma A; Riofrio M; Spielmann M; Jimeno J; Misset JL
Br J Cancer; 2006 Jun; 94(11):1610-4. PubMed ID: 16736024
[TBL] [Abstract][Full Text] [Related]
13. Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B; Cobo M; Camps C; Dómine M; Provencio M; Alberola V; Viñolas N; Rosell R; Tarón M; Gutiérrez-Calderón V; Lardelli P; Alfaro V; Nieto A; Isla D
Lung Cancer; 2012 Jun; 76(3):354-61. PubMed ID: 22197612
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
van Kesteren C; Twelves C; Bowman A; Hoekman K; López-Lázaro L; Jimeno J; Guzman C; Mathôt RA; Simpson A; Vermorken JB; Smyth J; Schellens JH; Hillebrand MJ; Rosing H; Beijnen JH
Anticancer Drugs; 2002 Apr; 13(4):381-93. PubMed ID: 11984084
[TBL] [Abstract][Full Text] [Related]
15. Phase I clinical and pharmacokinetic study of trabectedin and cisplatin in solid tumours.
Sessa C; Cresta S; Noberasco C; Capri G; Gallerani E; De Braud F; Zucchetti M; D'Incalci M; Locatelli A; Marsoni S; Corradino I; Minoia C; Zintl P; Gianni L
Eur J Cancer; 2009 Aug; 45(12):2116-22. PubMed ID: 19419856
[TBL] [Abstract][Full Text] [Related]
16. In vivo antitumour efficacy of MGI-114 (6-hydroxymethylacylfulvene, HMAF) in various human tumour xenograft models including several lung and gastric tumours.
Sato Y; Kashimoto S; MacDonald JR; Nakano K
Eur J Cancer; 2001 Jul; 37(11):1419-28. PubMed ID: 11435075
[TBL] [Abstract][Full Text] [Related]
17. Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
van Kesteren Ch; de Vooght MM; López-Lázaro L; Mathôt RA; Schellens JH; Jimeno JM; Beijnen JH
Anticancer Drugs; 2003 Aug; 14(7):487-502. PubMed ID: 12960733
[TBL] [Abstract][Full Text] [Related]
18. Ecteinascidin 743 induces protein-linked DNA breaks in human colon carcinoma HCT116 cells and is cytotoxic independently of topoisomerase I expression.
Takebayashi Y; Goldwasser F; Urasaki Y; Kohlhagen G; Pommier Y
Clin Cancer Res; 2001 Jan; 7(1):185-91. PubMed ID: 11205907
[TBL] [Abstract][Full Text] [Related]
19. In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients.
Izbicka E; Lawrence R; Raymond E; Eckhardt G; Faircloth G; Jimeno J; Clark G; Von Hoff DD
Ann Oncol; 1998 Sep; 9(9):981-7. PubMed ID: 9818072
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of trabectedin in treating ovarian cancer.
Teplinsky E; Herzog TJ
Expert Opin Pharmacother; 2017 Feb; 18(3):313-323. PubMed ID: 28140689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
